$11.21
-0.19-1.67%
At Close: -
$11.34
0.131.16%
After Hours: 4:04 PM EDT
15 minutes delayed
ADMA Biologics
ADMANASDAQ
ADMA Biologics (NASDAQ:ADMA) Stock, Analyst Ratings, Price Targets, Predictions
ADMA Biologics Inc has a consensus price target of $11, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from Mizuho, Raymond James, and Cantor Fitzgerald on June 20, 2024, May 10, 2024, and May 10, 2024. With an average price target of $11.33 between Mizuho, Raymond James, and Cantor Fitzgerald, there's an implied -0.06% downside for ADMA Biologics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
Raymond James
Cantor Fitzgerald
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for ADMA Biologics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/20/2024 | Buy Now | 23.46% | Mizuho | Anthony Petrone | $12 → $14 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | -11.82% | Raymond James | Elliot Wilbur | $8 → $10 | Maintains | Strong Buy | Get Alert |
| 05/10/2024 | Buy Now | -11.82% | Cantor Fitzgerald | Kristen Kluska | $8 → $10 | Maintains | Overweight | Get Alert |
| 05/10/2024 | Buy Now | -11.82% | HC Wainwright & Co. | Raghuram Selvaraju | $7.5 → $10 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 5.82% | Mizuho | Anthony Petrone | $10 → $12 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | -33.86% | HC Wainwright & Co. | Raghuram Selvaraju | $6 → $7.5 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | -11.82% | Mizuho | Anthony Petrone | $9 → $10 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | -29.45% | Cantor Fitzgerald | Kristen Kluska | $6.5 → $8 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | -47.09% | HC Wainwright & Co. | Raghuram Selvaraju | → $6 | Reiterates | Buy → Buy | Get Alert |
| 01/22/2024 | Buy Now | -20.63% | Mizuho | Anthony Petrone | $7 → $9 | Maintains | Buy | Get Alert |
| 01/09/2024 | Buy Now | -47.09% | HC Wainwright & Co. | Raghuram Selvaraju | $5 → $6 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | -47.09% | Cantor Fitzgerald | Kristen Kluska | → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 11/17/2023 | Buy Now | -55.91% | HC Wainwright & Co. | Raghuram Selvaraju | → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | -47.09% | Cantor Fitzgerald | Kristen Kluska | $5 → $6 | Maintains | Overweight | Get Alert |
| 08/10/2023 | Buy Now | -47.09% | Raymond James | Elliot Wilbur | $5 → $6 | Maintains | Strong Buy | Get Alert |
| 08/10/2023 | Buy Now | -55.91% | HC Wainwright & Co. | Raghuram Selvaraju | $4.5 → $5 | Maintains | Buy | Get Alert |
| 03/27/2023 | Buy Now | -60.32% | HC Wainwright & Co. | Raghuram Selvaraju | → $4.5 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | Buy Now | -60.32% | HC Wainwright & Co. | Raghuram Selvaraju | → $4.5 | Reiterates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | -60.32% | HC Wainwright & Co. | Raghuram Selvaraju | $4 → $4.5 | Maintains | Buy | Get Alert |
| 11/10/2022 | Buy Now | -47.09% | Mizuho | Anthony Petrone | $5 → $6 | Maintains | Buy | Get Alert |
| 10/13/2022 | Buy Now | -55.91% | Mizuho | Anthony Petrone | → $5 | Initiates | → Buy | Get Alert |
| 07/25/2022 | Buy Now | -64.73% | HC Wainwright & Co. | Raghuram Selvaraju | $6 → $4 | Maintains | Buy | Get Alert |
| 11/11/2021 | Buy Now | -55.91% | Raymond James | Elliot Wilbur | — | Upgrade | Outperform → Strong Buy | Get Alert |
| 11/09/2021 | Buy Now | -60.32% | Cantor Fitzgerald | Kristen Kluska | — | Initiates | → Overweight | Get Alert |
| 10/26/2021 | Buy Now | -55.91% | Raymond James | Elliot Wilbur | — | Maintains | Outperform | Get Alert |
| 08/12/2021 | Buy Now | -47.09% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
| 07/06/2021 | Buy Now | -38.27% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for ADMA Biologics (ADMA) stock?
The latest price target for ADMA Biologics (NASDAQ:ADMA) was reported by Mizuho on June 20, 2024. The analyst firm set a price target for $14.00 expecting ADMA to rise to within 12 months (a possible 23.46% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ADMA Biologics (ADMA)?
The latest analyst rating for ADMA Biologics (NASDAQ:ADMA) was provided by Mizuho, and ADMA Biologics maintained their buy rating.
When was the last upgrade for ADMA Biologics (ADMA)?
The last upgrade for ADMA Biologics Inc happened on November 11, 2021 when Raymond James raised their price target to $5. Raymond James previously had an outperform for ADMA Biologics Inc.
When was the last downgrade for ADMA Biologics (ADMA)?
There is no last downgrade for ADMA Biologics.
When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on June 20, 2024 so you should expect the next rating to be made available sometime around June 20, 2025.
Is the Analyst Rating ADMA Biologics (ADMA) correct?
While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $12.00 to $14.00. The current price ADMA Biologics (ADMA) is trading at is $11.34, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.